On Monday, Cidara Therapeutics Inc (NASDAQ: CDTX) was 9.47% up from the session before settling in for the closing price of $50.53. A 52-week range for CDTX has been $10.14 – $56.83.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 1.30% over the past five years. When this article was written, the company’s average yearly earnings per share was at 71.53%. With a float of $13.09 million, this company’s outstanding shares have now reached $22.12 million.
Let’s look at the performance matrix of the company that is accounted for 38 employees. In terms of profitability, gross margin is 81.13%, operating margin of -35743.71%, and the pretax margin is -61454.97%.
Cidara Therapeutics Inc (CDTX) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Cidara Therapeutics Inc stocks. The insider ownership of Cidara Therapeutics Inc is 40.83%, while institutional ownership is 47.21%. The most recent insider transaction that took place on Jun 26 ’25, was worth 99,999,988. In this transaction Director of this company bought 2,272,727 shares at a rate of $44.00, taking the stock ownership to the 3,365,523 shares. Before that another transaction happened on Jun 02 ’25, when Company’s Director bought 2,270 for $21.71, making the entire transaction worth $49,281. This insider now owns 2,270 shares in total.
Cidara Therapeutics Inc (CDTX) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 71.53% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 36.71% during the next five years compared to 1.30% growth over the previous five years of trading.
Cidara Therapeutics Inc (NASDAQ: CDTX) Trading Performance Indicators
You can see what Cidara Therapeutics Inc (CDTX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.87. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4078.47.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -29.07, a number that is poised to hit -1.95 in the next quarter and is forecasted to reach -7.58 in one year’s time.
Technical Analysis of Cidara Therapeutics Inc (CDTX)
Cidara Therapeutics Inc (NASDAQ: CDTX) saw its 5-day average volume 0.94 million, a positive change from its year-to-date volume of 0.35 million. As of the previous 9 days, the stock’s Stochastic %D was 84.44%.
During the past 100 days, Cidara Therapeutics Inc’s (CDTX) raw stochastic average was set at 96.37%, which indicates a significant increase from 89.09% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 5.06 in the past 14 days, which was higher than the 2.17 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $30.72, while its 200-day Moving Average is $21.84. Nevertheless, the first resistance level for the watch stands at $57.57 in the near term. At $59.82, the stock is likely to face the second major resistance level. The third major resistance level sits at $63.89. If the price goes on to break the first support level at $51.25, it is likely to go to the next support level at $47.18. Assuming the price breaks the second support level, the third support level stands at $44.93.
Cidara Therapeutics Inc (NASDAQ: CDTX) Key Stats
There are 20,164K outstanding shares of the company, which has a market capitalization of 1.22 billion. As of now, sales total 1,280 K while income totals -169,830 K. Its latest quarter income was 0 K while its last quarter net income were -23,480 K.
